CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of 0.00% and +412.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?